GSK and Actelion - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 report featuring GlaxoSmithKline's $3.25 billion partnership with Actelion.Who: GlaxoSmithKline
With: Actelion
What: $3.25B partnership

Summary: In July, GlaxoSmithKline agreed top pay Acetlion â‚£150 million up front and up to â‚£415 million more depending on Phase III data for its insomnia drug almorexant. Actelion could get another â‚£2.7 billion in additional milestone payments based on almorexant results for insomnia and two other major indications. As part of the deal, GSK gets worldwide rights to the drug outside of Japan.

GSK and Actelion - Top 10 deals of 2008
Read more on

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.